trending Market Intelligence /marketintelligence/en/news-insights/trending/9PQGILbpqa1yJpMDwTBeOQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bausch Health's Arazlo lotion for acne snags US FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bausch Health's Arazlo lotion for acne snags US FDA approval

Bausch Health Cos. Inc.'s Arazlo Lotion has been approved by the U.S. Food and Drug Administration to treat acne vulgaris in patients who are 9 and older.

Arazlo, also known as tazarotene 0.045%, was developed by Laval, Quebec-based Bausch's dermatology business Ortho Dermatologics Inc. and will launch in the first half of 2020 "to coincide with the start of acne season," Ortho Dermatologics President Bill Humphries said in a Dec. 19 press release.

During clinical trials, Arazlo improved the severity of noninflammatory and inflammatory lesions compared to a placebo drug, and also matched the efficacy and safety of a different acne treatment called Tazorac Cream 0.1%.

Acne, the most common skin condition in the U.S., affects about 50 million Americans. Acne stems from plugged hair follicles, leading to whiteheads, blackheads or pimples on the face, forehead, chest, upper back and shoulders.